Entera Bio (ENTX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.99 mm	6.99 mm	6.99 mm	6.99 mm	6.99 mm	6.99 mm
Cash burn (monthly)	713.67 k	56.92 k	1.01 mm	770.25 k	718.00 k	664.00 k
Cash used (since last report)	3.06 mm	243.68 k	4.31 mm	3.30 mm	3.07 mm	2.84 mm
Cash remaining	3.94 mm	6.75 mm	2.68 mm	3.70 mm	3.92 mm	4.15 mm
Runway (months of cash)	5.5	118.6	2.7	4.8	5.5	6.3

Beta Read what these cash burn values mean

Financial data from Entera Bio earnings reports.

Institutional ownership, Q2 2024

ENTX institutional ownership history Ownership history

20.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	16	16	–
Opened positions	5	14	-64.3%
Closed positions	5	0	NEW
Increased positions	2	0	NEW
Reduced positions	3	0	NEW

13F shares	Current	Prev Q	Change
Total value	9.73 bn	6.95 bn	+39.8%
Total shares	7.69 mm	6.66 mm	+15.5%
Total puts	0.00	0.00
Total calls	0.00	3.90 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Knoll Capital Management	3.88 mm	$7.14 bn	0.0%
Centillion Fund	2.40 mm	$3.24 mm	0.0%
Schonfeld Strategic Advisors	671.76 k	$1.24 bn	NEW
Parkman Healthcare Partners	401.52 k	$738.79 mm	NEW
UBS UBS	167.62 k	$308.43 mm	+11.8%
Renaissance Technologies	57.60 k	$105.98 mm	-23.1%
Susquehanna International	28.86 k	$53.10 mm	-44.1%
Geode Capital Management	17.60 k	$32.38 mm	0.0%
Advisor	16.78 k	$36.74 mm	+1018.5%
PNC The PNC Financial Services Group, Inc.	13.00 k	$23.92 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Schonfeld Strategic Advisors	671.76 k	+671.76 k	NEW
Parkman Healthcare Partners	401.52 k	+401.52 k	NEW
Susquehanna International	28.86 k	-22.77 k	-44.1%
Virtu Financial	0.00	-22.04 k	EXIT
Millennium Management	0.00	-19.51 k	EXIT
UBS UBS	167.62 k	+17.75 k	+11.8%
Renaissance Technologies	57.60 k	-17.30 k	-23.1%
Advisor	16.78 k	+15.28 k	+1018.5%
Citadel Advisors	0.00	-12.50 k	EXIT
CIBC World Markets	12.50 k	+12.50 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ENTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jan 25	Gerald M Ostrov	Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	0	8,038	0.00	46,936
15 Jan 25	Gerald M Ostrov	Stock Option Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	2.28	28,509	65.00 k	28,509
15 Jan 25	Yonatan Malca	Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	0	8,216	0.00	47,259
15 Jan 25	Yonatan Malca	Stock Option Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	2.28	28,509	65.00 k	28,509
15 Jan 25	Lieberman Gerald M	Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	0	10,717	0.00	276,208
15 Jan 25	Lieberman Gerald M	Stock Option Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	2.28	28,509	65.00 k	28,509
15 Jan 25	Haya Taitel	Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	0	6,922	0.00	64,650
15 Jan 25	Haya Taitel	Stock Option Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	2.28	28,509	65.00 k	28,509
15 Jan 25	Sean Ellis	Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	0	7,100	0.00	134,727
15 Jan 25	Sean Ellis	Stock Option Ordinary Shares, par value NIS 0.0000769 per share	Grant	Acquire A	No	No	2.28	28,509	65.00 k	28,509

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Entera Bio, Maintains $10 Price Target

11 Nov 24

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price target.